NCT05256225

Testing the Addition of Herceptin Hylecta or Phesgo to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or Carcinosarcoma

RecruitingPHASE3INTERVENTIONAL

Trial Details

Start: 2022-11-16Est. Completion: 2027-10-31

Enrollment target: 360 participants

Locations

University of Alabama at Birmingham Cancer Center, Birmingham, Alabama, United States
Alaska Women's Cancer Care, Anchorage, Alaska, United States
Banner University Medical Center - Tucson, Tucson, Arizona, United States
University of Arizona Cancer Center-North Campus, Tucson, Arizona, United States
University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States
Sutter Auburn Faith Hospital, Auburn, California, United States
Alta Bates Summit Medical Center-Herrick Campus, Berkeley, California, United States
John Muir Medical Center-Concord, Concord, California, United States
City of Hope Comprehensive Cancer Center, Duarte, California, United States
City of Hope Seacliff, Huntington Beach, California, United States
UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care, Irvine, California, United States
City of Hope at Irvine Lennar, Irvine, California, United States
Kaiser Permanente-Irvine, Irvine, California, United States
City of Hope at Long Beach Elm, Long Beach, California, United States

Other microbiome trials you might be interested in

Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial CarcinomaPhase 2Recruiting

Endometrial AdenocarcinomaEndometrial Clear Cell AdenocarcinomaEndometrial Dedifferentiated CarcinomaEndometrial Endometrioid AdenocarcinomaEndometrial Mixed Cell AdenocarcinomaEndometrial Mucinous AdenocarcinomaEndometrial Undifferentiated CarcinomaEndometrioid AdenocarcinomaRecurrent Endometrial Carcinoma

This phase II trial tests whether the combination of nivolumab and ipilimumab is better than nivolumab alone to shrink t…

Birmingham, United StatesEst. completion Jul 30, 2032

View Trial →

A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29)

Apply or Learn More on ClinicalTrials.gov

MicrobiomeTrials does not provide medical advice. Always consult your doctor before joining a clinical trial.